---
name: spec_092_phase_d_complete_2026_05_13
description: Spec 092 Phase D (forward returns analysis) shipped 2026-05-13
metadata: 
  node_type: memory
  type: project
  status: shipped
  date: 2026-05-13
  commits: 
    - "3e8ac686: feat(bioshort): Spec 092 Phase D — Forward returns analysis"
  originSessionId: 64125f0f-c9ea-4206-bd73-07c2f93a88dc
---

## Phase D: Forward Returns Analysis — COMPLETE

**Shipped:** 2026-05-13 (commit `3e8ac686`)  
**Branch:** origin/main  
**Input:** Panel from Phase C (146 snapshots, 2024-10-18 → 2026-05-13)  
**Status:** TERMINAL PHASE (Phase A–D all shipped)  

## Implementation Summary

### Code Changes

**tools/build_bioshort_forward_analysis.py** (new):
- Load PIT-safe price history from dual sources:
  - `data/indices_prices.csv` (XBI 517 prices)
  - `production_data/price_history.csv` (merged: XBI 1598, IBB 274 prices)
- Join forward returns to feature panel:
  - forward_1d: T+1 return %
  - forward_5d: T+5 return %
  - forward_20d: T+20 return %
  - max_drawdown_20d: worst intraday draw over 20d window
  - realized_vol_20d: annualized volatility of daily returns
- Compute descriptive statistics:
  - Verdict accuracy: % of samples where forward_5d >= 0
  - Median returns by verdict and confidence
  - Forward return statistics (global medians)

### Output Artifacts

**artifacts/research/bioshort_backfill/forward_analysis/**
```
panel_with_returns.csv              # 146 rows, 21 columns (16 features + 5 forward columns)
forward_analysis_report.json        # schema v1, pseudo-PIT caveat, stats by verdict/confidence
```

### Key Findings (Pseudo-PIT)

**Dataset Coverage:**
- Total panel rows: 146
- Rows with forward_5d: 129 (88%)
- Rows with forward_20d: 114 (78%)

**Verdict Accuracy (DEFER — only verdict in panel):**
- N: 129 samples
- Hit rate T+5 (forward_5d >= 0): 60.5%
- Median T+1 return: -0.09%
- Median T+5 return: 0.63%
- Median T+20 return: 2.49%

**Confidence Distribution (all LOW confidence):**
- N: 129 samples
- Median T+1: -0.09%
- Median T+5: 0.63%
- Median T+20: 2.49%

**Global Forward Return Statistics (XBI portfolio proxy):**
- Median T+1: -0.05%
- Median T+5: +0.63%
- Median T+20: +2.49%
- Median max drawdown (20d): -2.86%
- Median realized vol (annualized): 26.31%

### Pseudo-PIT Caveat (Per Spec 092 §A6)

Features computed using `tools/biotech_hedge_report.py` logic against **historical snapshot inputs**, not as-of-date producer runs. This is acceptable for:
- ✅ Descriptive panel analysis
- ✅ Hypothesis generation
- ✅ Diagnostic dashboards

NOT acceptable for:
- ❌ Promotion claims (requires Checklist v2 on forward shadow)
- ❌ Live allocation decisions
- ❌ Risk limits or position sizing

Forward-return analysis is labeled "descriptive" / "pseudo-PIT" in artifacts. No promotion path supported for Phase D output per Spec 092 constraints.

### Verdict on Bioshort Signal

**Finding:** DEFER verdict shows 60.5% hit rate T+5 (129/146 recommendations, 78 hits). Median return +0.63% over 5d, +2.49% over 20d. Modest positive signal, but:

1. **Limited scope:** Only 146 historical snapshots; all recommendations are DEFER (no variance in verdict to test discriminatory power)
2. **Pseudo-PIT bias:** Features computed with current logic on old snapshots; cannot make promotion claim
3. **Confidence low:** All samples LOW confidence; no evidence confidence level improves hit rate
4. **Volatility high:** Realized vol 26% annualized; drawdown -2.86% median intraday

**Conclusion:** Bioshort hedge-recommendation feature carries modest positive signal (60.5% hit rate), but pseudo-PIT constraint prevents promotion. Forward shadow (Phase E—not in Spec 092 scope) would be required to convert descriptive finding into actionable alpha claim.

## Outputs Disposition

**artifacts/research/bioshort_backfill/**
- `panel.csv` (Phase C feature panel, 146 rows)
- `backfill_manifest.json` (Phase C metadata)
- `reports/` (hedge_report JSON/MD per snapshot)
- **NEW: `forward_analysis/`**
  - `panel_with_returns.csv` (labeled panel)
  - `forward_analysis_report.json` (verdict accuracy + stats)

All artifacts PIT-safe and descriptive-only (no operational routing).

## Spec 092 Status: COMPLETE

| Phase | Scope | Status | Commit | Date |
|-------|-------|--------|--------|------|
| A | Design + inventory | SHIPPED | (doc) | 2026-05-07 |
| B | Research-mode flag | SHIPPED | 47041a6f | 2026-05-13 |
| C | Panel backfill | SHIPPED | 34902dbb | 2026-05-13 |
| D | Forward analysis | SHIPPED | 3e8ac686 | 2026-05-13 |

All gating criteria met:
- ✅ Phase A approved
- ✅ Spec 087 B1b first-fire validation passed
- ✅ Phase B verified (isolation confirmed)
- ✅ Phase C panel complete (146/146 success)
- ✅ Phase D analysis complete (forward returns computed)

## Next Steps

1. **Observation window:** Monitor whether bioshort hedge findings correlate with live portfolio performance (forward shadow, not in spec)
2. **Potential Phase E (future):** Implement prospective forward shadow on live recommendations to convert pseudo-PIT finding into promotion-eligible evidence
3. **Archive:** Store all Phase D artifacts in research dir; no operational integration planned

## QA Notes

- All pre-commit hooks (black, isort, flake8, detect-secrets) passing
- Price data sources: 1598 XBI prices, 274 IBB prices (merged from indices + production)
- Data quality: 88% forward_5d coverage, 78% forward_20d coverage
- Pseudo-PIT label explicitly documented in all output JSON
- No mutations to live scoring/ranker/selection (research-only artifact path)
